Antigen clearance for evaluation of treatment of histoplasmosis. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Antigen clearance for evaluation of treatment of histoplasmosis.

Abstr Gen Meet Am Soc Microbiol. 1994;94:605 (abstract no. F-95). Unique Identifier : AIDSLINE ASM94/94313117
Blair R; Garringer T; Limjoco M; Korzun A; Hafner R; Wheat J; Indiana University, Indianapolis.

Abstract: Evaluation of new antifungal agents may be assisted by measurement of Histoplasma antigen clearance. We compared antigen clearance in patients treated successfully with itraconazole to that in historical controls treated with amphotericin B. Patients receiving itra were participants in an AIDS Clinical Trials Group protocol. The historical control group included AIDS patients treated with ampho B from 1988 to 1992. Antigen clearance was measured by radioimmunoassay, testing samples at baseline and at the end of induction treatment in a single assay to allow direct comparison. Antigenuria cleared more rapidly in patients treated with ampho B than with itra. TABULAR DATA, SEE ABSTRACT VOLUME. Antigenemia clearance was similar in both groups. This rate of clearance of antigen correlates with clinical evidence of more rapid response to treatment with ampho B than itra, namely defervescence. Clearance of antigen may complement clinical and cultural markers for evaluation of antifungal therapy for histoplasmosis.
Keywords: Acquired Immunodeficiency Syndrome/THERAPY Amphotericin B/*THERAPEUTIC USE Antigens, Fungal/*BLOOD/URINE AIDS-Related Opportunistic Infections/*PREVENTION & CONTROL Comparative Study Histoplasma/*IMMUNOLOGY Histoplasmosis/*PREVENTION & CONTROL Human Itraconazole/*THERAPEUTIC USE Metabolic Clearance Rate CLINICAL TRIAL ABSTRACTKWDacquiredimmunodeficiencysyndrome/therapyamphotericinb/KWDtherapeuticuseantigens,fungal/KWDblood/urineaids-relatedopportunisticinfections/KWDprevention&controlcomparativestudyhistoplasma/KWDimmunologyhistoplasmosis/KWDprevention&controlhumanitraconazole/KWDtherapeuticusemetabolicclearancerateclinicaltrialabstract
941030
M94A0837

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .